全文获取类型
收费全文 | 27298篇 |
免费 | 1621篇 |
国内免费 | 256篇 |
专业分类
耳鼻咽喉 | 235篇 |
儿科学 | 539篇 |
妇产科学 | 578篇 |
基础医学 | 2784篇 |
口腔科学 | 665篇 |
临床医学 | 1933篇 |
内科学 | 7872篇 |
皮肤病学 | 352篇 |
神经病学 | 2382篇 |
特种医学 | 1041篇 |
外科学 | 5145篇 |
综合类 | 54篇 |
一般理论 | 5篇 |
预防医学 | 999篇 |
眼科学 | 518篇 |
药学 | 1626篇 |
中国医学 | 55篇 |
肿瘤学 | 2392篇 |
出版年
2023年 | 271篇 |
2022年 | 233篇 |
2021年 | 911篇 |
2020年 | 585篇 |
2019年 | 838篇 |
2018年 | 1000篇 |
2017年 | 727篇 |
2016年 | 880篇 |
2015年 | 899篇 |
2014年 | 1218篇 |
2013年 | 1497篇 |
2012年 | 2284篇 |
2011年 | 2170篇 |
2010年 | 1250篇 |
2009年 | 1202篇 |
2008年 | 1874篇 |
2007年 | 1816篇 |
2006年 | 1704篇 |
2005年 | 1692篇 |
2004年 | 1591篇 |
2003年 | 1360篇 |
2002年 | 1223篇 |
2001年 | 120篇 |
2000年 | 118篇 |
1999年 | 150篇 |
1998年 | 164篇 |
1997年 | 137篇 |
1996年 | 129篇 |
1995年 | 149篇 |
1994年 | 123篇 |
1993年 | 119篇 |
1992年 | 88篇 |
1991年 | 55篇 |
1990年 | 66篇 |
1989年 | 50篇 |
1988年 | 40篇 |
1987年 | 36篇 |
1986年 | 42篇 |
1985年 | 38篇 |
1984年 | 34篇 |
1983年 | 33篇 |
1982年 | 50篇 |
1981年 | 28篇 |
1980年 | 27篇 |
1979年 | 18篇 |
1978年 | 12篇 |
1976年 | 11篇 |
1975年 | 8篇 |
1974年 | 12篇 |
1933年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Paolo Fontana Francesco Fioravanti Passaretti Marianna Maioli Giuseppina Cantalupo Francesca Scarano Fortunato Lonardo 《World Journal of Medical Genetics》2020,9(1):1-11
Wiedemann-Steiner syndrome (OMIM #605130) is a rare congenital malformation syndrome characterized by hypertrichosis cubiti associated with short stature; consistent facial features, including long eyelashes, thick or arched eyebrows with a lateral flare, wide nasal bridge, and downslanting and vertically narrow palpebral fissures; mild to moderate intellectual disability; behavioral difficulties; and hypertrichosis on the back. It is caused by heterozygous pathogenic variants in KMT2A. This gene has an established role in histone methylation, which explains the overlap of Wiedemann-Steiner syndrome with other chromatinopathies, a heterogeneous group of syndromic conditions that share a common trigger: The disruption of one of the genes involved in chromatin modification, leading to dysfunction of the epigenetic machinery. 相似文献
32.
Marinella Lauriola Arianna Pani Giovanbattista Ippoliti Andrea Mortara Stefano Milighetti Marjieh Mazen Gianluca Perseghin Daniele Pastori Paolo Grosso Francesco Scaglione 《CTS Clinical and Translational Science》2020,13(6):1071
Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection do exist. We performed a retrospective single‐center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID‐19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications. The primary end point was in‐hospital death. Mean age was 71.8 ± 13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment group, and 102 in HCQ + azithromycin treatment group (log rank test for Kaplan–Meier curve P < 0.001). At multivariable Cox proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence interval (CI) 1.035–1.079, P < 0.001), mechanical ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823–4.074, P < 0.001), and C reactive protein above the median (HR 2.191, 95% CI 1.479–3.246, P < 0.001) were directly associated with death, whereas use of HCQ + azithromycin (vs. no treatment; HR 0.265, 95% CI 0.171–0.412, P < 0.001) was inversely associated. In this study, we found a reduced in‐hospital mortality in patients treated with a combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings.The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection is spreading worldwide since December 2019 and still no proven effective therapy has been found. First therapy proposed to treat coronavirus disease 2019 (COVID‐19) has been the association of lopinavir‐ritonavir, a protease inhibitor approved for HIV infection. However, Cao et al. observed no benefit comparing lopinavir‐ritonavir treatment of hospitalized patients with severe COVID‐19, 1 and this treatment is currently not recommended. Currently, only remdesivir has been approved for COVID‐19 treatment, as it reduced recovery time by 4 days in 1,063 patients randomized to either remdesivir 200 mg loading dose followed by 100 mg daily or placebo for up to 10 days 2 with a similar rate of adverse events between the 2 groups. 3 However, no effect on in‐hospital mortality was found.Chloroquine and its derivative hydroxychloroquine (HCQ), based on few preclinical studies, have also been proposed as therapies for COVID‐19. A Chinese randomized trial in patients with mild disease showed a significantly shorter recovery time in the group treated with HCQ vs. the standard of care along with a radiological improvement. 4 Differently, a retrospective study performed in the United States Veterans Health Administration medical centers found an increased mortality associated with the treatment with HCQ. 5 Moreover, an observational study has shown no significant association between HCQ use and risk of intubation or death. 6 Furthermore, a recent randomized controlled trial has found no differences between patients treated with HCQ plus the standard of care vs. the standard of care alone in terms of virus elimination. 7 On the basis of a very small nonrandomized study, azithromycin has been proposed as possible treatment in association with HCQ. 8 Azithromycin, is an antibiotic belonging to the class of macrolides, with some proven efficacy in acute respiratory distress syndrome. 9 , 10 It is known to have immunomodulatory properties through the polarization of macrophages toward the reparative state 11 and the reduction in the production of pro‐inflammatory cytokines, such as IL‐8, IL‐6, TNF alpha, 12 and iNOS expression. 13 Recently, two large retrospective studies evaluating in‐hospital mortality associated with the use of the combination of HCQ and azithromycin (or another macrolide, such as clarithromycin), have shown no benefits. 14 Despite the lack of a proven clinical efficacy and some concerns regarding the possible QT prolongations caused by the association of HCQ and azithromycin, 15 given the low price and the wide availability, the association of these two drugs has become the most used treatment in patients with moderate‐severe COVID‐19.Because of the urgent need to find answers to the many questions posed by the fight to SARS‐CoV2 infection and some negative evidences regarding the use of HCQ, we here propose a retrospective observational study to assess the efficacy of the combination of HCQ plus azithromycin for hospitalized patients with medium‐severe COVID‐19. 相似文献
33.
34.
Javier Jarazo PhD Kyriaki Barmpa MSc Jennifer Modamio PhD Cláudia Saraiva PhD Sònia Sabaté-Soler MSc Isabel Rosety MSc Anne Griesbeck PhD Florian Skwirblies BSc Gaia Zaffaroni PhD Lisa M. Smits PhD Jihui Su BSc Jonathan Arias-Fuenzalida PhD Jonas Walter PhD Gemma Gomez-Giro PhD Anna S. Monzel PhD Xiaobing Qing PhD Armelle Vitali MSc Gerald Cruciani MSc Ibrahim Boussaad PhD Francesco Brunelli PhD Christian Jäger PhD Aleksandar Rakovic PhD Wen Li PhD Lin Yuan PhD Emanuel Berger PhD Giuseppe Arena PhD Silvia Bolognin PhD Ronny Schmidt PhD Christoph Schröder PhD Paul M.A. Antony PhD Christine Klein MD Rejko Krüger MD Philip Seibler PhD Jens C. Schwamborn PhD 《Movement disorders》2022,37(1):80-94
35.
36.
F. Murina R. Felice S. Di Francesco L. Nelvastellio I. Cetin 《Gynecological endocrinology》2020,36(5):431-435
AbstractThis study is a single-center, retrospective analysis of postmenopausal women presenting with dyspareunia and vulvar pain, aiming to evaluate relative effectiveness of vestibular CO2 laser therapy as a treatment. Three monthly sessions of laser were performed to each patient and thereafter a three-months follow-up was stablished. A total number of 72 patients undergoing vestibular laser treatment were recruited from patient files in the period between 2016 and 2018. Among these, 39 women also received a concomitant treatment with ospemifene (60?mg/day) during the study period. There was a statistically significant reduction of all the symptoms in both groups up to the three month follow-up. Regarding dryness and dyspareunia, the relief tent to be more prominent in the ospemifene?+?laser group at all follow-ups and remained statistically significant at three-month follow-up. Specifically, vestibular dryness was significantly lower in the ospemifene?+?laser group compared with the laser treatment group (?87% vs???34%, respectively), and the vestibular health score started declining faster in the ospemifene?+?laser group. Although, additional research is needed to understand the mechanism of action, our data shows that a combination regimen of laser and ospemifene may improve clinical effectiveness for long-term treatment of symptoms associated with the under-recognized genitourinary syndrome of menopause. 相似文献
37.
38.
39.
40.